Clinical trial

Imipramine on ER+ve and Triple Negative Breast Cancer

NCT03122444

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-07-05

PhaseEARLY_PHASE1

Study timeline

Study start (actual)2019-07-05Date precision: day

Registry last updated2023-06-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

ImipramineDRUG · verified · RxNorm: imipramine

Sponsors & collaborators

The University of Texas Health Science Center at San Antoniolead sponsor

Mapped research locations

San AntonioTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03122444 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.